目的 探讨注射用丹参多酚酸对新发缺血性脑卒中患者血运重建后脑缺血再灌注损伤的保护作用。方法 选取2020年1月—2022年6月河北省唐山市古冶区中医医院收治的新发缺血性脑卒中并血运重建后发生脑缺血再灌注损伤的患者124例为研究对象，根据治疗药物不同将患者分为对照组和试验组，每组各62例。对照组患者在常规治疗和溶栓/取栓治疗基础上加用丹红注射液（40 mL丹红注射液＋250 mL 0.9%氯化钠注射液，静脉滴注，每日1次），试验组患者在常规治疗和溶栓/取栓治疗基础上加用注射用丹参多酚酸（0.13 g注射用丹参多酚酸＋250 mL 0.9%氯化钠注射液，静脉滴注，每日1次），两组均连续治疗14 d。分别于治疗前及治疗14 d测定两组患者血清中脑型肌酸激酶同工酶（CK-BB）、中枢神经特异性蛋白S-100β（S-100β）、肿瘤坏死因子（TNF-α）、谷氨酸（Glu）、转化生长因子-β1（TGF-β1）、白细胞介素-1（IL-1）与白细胞介素-10（IL-10）水平，核磁共振（MRI）检查并计算相对表观扩散系数值（rADC），根据美国国立卫生研究院卒中量表（NIHSS）评估治疗效果，统计不良反应。结果 治疗前，两组患者各项指标比较，差异均无统计学意义（P＞0.05）；治疗14 d，两组患者血清CK-BB、S-100β、TNF-α、TGF-β1、Glu、IL-1、IL-10水平均较本组治疗前显著降低（P＜0.05），且试验组各项指标水平均低于对照组（P＜0.05）；治疗14 d，两组患者rADC值均较本组治疗前显著升高（P＜0.05），且试验组显著高于对照组（P＜0.05）。对照组治疗总有效率为64.52%，试验组治疗总有效率为74.19%，两组比较差异显著（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 注射用丹参多酚酸可以有效减轻新发脑卒中患者血运重建后脑缺血再灌注损伤，提高疗效，对脑组织有保护作用。

Objective To investigate the protective effect of Salvianolic Acid for Injection on cerebral ischemia-reperfusion injury after revascularization in newly diagnosed ischemic stroke patients. Methods A total of 124 patients with new ischemic stroke and cerebral ischemia-reperfusion injury after blood circulation reconstruction who were admitted to Guye District Hospital of Traditional Chinese Medicine in Tangshan from January 2020 to June 2022 were selected as the research objects. According to different therapeutic drugs, the patients were divided into control group and experimental group, with 62 cases in each group. The control group patients were treated with Danhong Injection (40 mL Danhong Injection + 250 mL 0.9% Sodium Chloride Injection, intravenous drip, once a day) on the basis of routine treatment and thrombolysis/thrombectomy treatment. The experimental group patients were treated with Salvianolic Acid for Injection (0.13 g Salvianolic Acid for Injection + 250 mL 0.9% Sodium Chloride Injection, intravenous drip, once a day) on the basis of routine treatment and thrombolysis/thrombectomy treatment. Both groups were continuously treated for 14 days. Serum levels of midbrain creatine kinase isozyme (CK-BB), central nerve specific protein S-100 β (S-100 β), tumor necrosis factor-α (TNF-α), glutamic acid (Glu), transforming growth factor- β 1 (TGF-β1), interleukin-1 (IL-1) and interleukin 10 (IL-10) were measured before treatment and 14 days after treatment in the two groups. Nuclear Magnetic Resonance Imaging (MRI) was examined and relative apparent diffusion coefficient (rADC) was calculated. Treatment effect was evaluated according to the National Institutes of Health Stroke Scale (NIHSS), and adverse reactions was observed. Results Before treatment, there was no statistically significant difference in various indicators between the two groups of patients (P＞0.05). After 14 days of treatment, serum levels of CK-BB, S-100 β, TNF-α, Glu, TGF- β 1, IL-1 and IL-10 were significantly reduced compared to before treatment in same group (P＜0.05). Levels of above various indicators in the experimental group were lower than those in the control group (P＜0.05). After 14 days of treatment, the rADC values of both groups of patients were significantly higher than before treatment (P＜0.05), and the experimental group was significantly higher than the control group (P＜0.05). The total effective rate of the control group was 64.52%, while the total effective rate of the experimental group was 74.19%. The difference between the two groups was significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Salvianolic Acid for Injection can effectively alleviate cerebral ischemiareperfusion injury after revascularization in newly diagnosed stroke patients, improve therapeutic efficacy, and have a protective effect on brain tissue.

R971